Keywords
bacterium-like particles
antigen presentation
adjuvants
adaptive immune response
How to Cite
Abstract
Introduction: The development of a vaccine against herpes simplex virus type 2 (HSV-2), which causes a lifelong sexually transmitted infection, would be a great step to improve sexual and reproductive health worldwide. Objectives: To study the mucosal and systemic immune responses induced by an experimental vaccine consisting of bacterium-like particles (BLP) derived from lactobacilli, which retain their peptidoglycan matrix and expose the HSV-2 gD antigen on their surface thanks to its fusion with LysM domains. Materials and methods: Six-week-old BALB/c mice were nasally immunized with the His-AcglugD- BLP027 complex on days 0, 14, and 28. As a control, His-Acglu-gD was administered intranasally or His-gD with complete Freund’s adjuvant peritoneally. The levels of specific immunoglobulins in serum and in bronchoalveolar lavage (BAL), as well as the production of cytokines by splenocytes after the antigenic restimulation, were evaluated. Results: The experimental vaccine induced higher levels of IgA in BAL than in mice immunized with Freund’s adjuvant. Conclusions: This new antigen presentation system could be a useful tool for the development of mucosal vaccines that stimulate local and distant immunity.
References
Kardani K, Basimi P, Fekri M, Bolhassani A. Antiviral therapy for the sexually transmitted viruses: recent updates on vaccine development. Expert Rev Clin Pharmacol. 2020;13(9):1001-46. doi:10.1080/17512433.2020.1814743
Johnston C, Gottlieb SL, Wald A. Status of vaccine research and development of vaccines for herpes simplex virus. Vaccine. 2016;34(26):2948-52. doi:10.1016/j.vaccine.2015.12.076
Spicknall IH, Looker KJ, Gottlieb SL, Chesson HW, Schiffer JT, Elmes J, et al. Review of mathematical models of HSV-2 vaccination: Implications for vaccine development. Vaccine. 2019;37(50):7396-407. doi: 10.1016/j.vaccine.2018.02.067
Stinn T, Kuntz S, Varon D, Huang ML, Selke S, Njikan S, et al. Subclinical Genital Herpes Shedding in HIV/Herpes Simplex Virus 2-Coinfected Women during Antiretroviral Therapy Is Associated with an Increase in HIV Tissue Reservoirs and Potentially Promotes HIV Evolution. J Virol. 2020;95(1). doi:10.1128/JVI.01606-20
LaTourette PC, 2nd, Awasthi S, Desmond A, Pardi N, Cohen GH, Weissman D, et al. Protection against herpes simplex virus type 2 infection in a neonatal murine model using a trivalent nucleoside-modified mRNA in lipid nanoparticle vaccine. Vaccine. 2020;38(47):7409-13. doi: 10.1016/j.vaccine.2020.09.079
Byrne CM, Gantt S, Coombs D. Effects of spatiotemporal HSV-2 lesión dynamics and antiviral treatment on the risk of HIV-1 acquisition. PLoS Comput Biol. 2018;14(4):e1006129. doi: 10.1371/journal.pcbi.1006129
Egan KP, Hook LM, Naughton A, Pardi N, Awasthi S, Cohen GH, et al. An HSV-2 nucleoside-modified mRNA genital herpes vaccine containing glycoproteins gC, gD, and gE protects mice against HSV-1 genital lesions and latent infection. PLoS Pathog. 2020;16(7):e1008795. doi: 10.1371/journal.ppat.1008795
Bi J, Li F, Zhang M, Wang H, Lu J, Zhang Y, et al. An HIV-1 vaccine based on bacterium-like particles elicits Env-specific mucosal immune responses. Immunol Lett. 2020;222:29-39. doi: 10.1016/j.imlet.2020.03.002
Sato A, Suwanto A, Okabe M, Sato S, Nochi T, Imai T, et al. Vaginal memory T cells induced by intranasal vaccination are critical for protective T cell recruitment and prevention of genital HSV-2 disease. J Virol. 2014;88(23):13699-708. doi: 10.1128/JVI.02279-14
Lycke N. Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol. 2012;12(8):592-605. doi: 10.1038/nri3251
Villena J, Chiba E, Tomosada Y, Salva S, Marranzino G, Kitazawa H, et al. Orally administered Lactobacillus rhamnosus modulates the respiratory immune response triggered by the viral pathogen-associated molecular pattern poly(I:C). BMC Immunol. 2012;13:53. doi: 10.1186/1471-2172-13-53
Villena J, Medina M, Vintini E, Alvarez S. Stimulation of respiratory immunity by oral administration of Lactococcus lactis. Can J Microbiol. 2008;54(8):630-8. doi: 10.1139/w08-052
Villena J, Racedo S, Aguero G, Bru E, Medina M, Alvarez S. Lactobacillus casei improves resistance to pneumococcal respiratory infection in malnourished mice. J Nutr. 2005;135(6):1462-9. doi: 10.1093/jn/135.6.1462
Tonetti FR, Islam MA, Vizoso-Pinto MG, Takahashi H, Kitazawa H, Villena J. Nasal priming with immunobiotic lactobacilli improves the adaptive immune response against influenza virus. Int Immunopharmacol. 2020;78:106115. doi: 10.1016/j.intimp.2019.106115
Villena J, Barbieri N, Salva S, Herrera M, Alvarez S. Enhanced immune response to pneumococcal infection in malnourished mice nasally treated with heat-killed Lactobacillus casei. Microbiol Immunol. 2009;53(11):636-46. doi: 10.1111/j.1348-0421.2009.00171.x
Raya Tonetti F, Arce L, Salva S, Alvarez S, Takahashi H, Kitazawa H, et al. Immunomodulatory Properties of Bacterium-Like Particles Obtained From Immunobiotic Lactobacilli: Prospects for Their Use as Mucosal Adjuvants. Front Immunol. 2020;11:15. doi: 10.3389/fimmu.2020.00015.
Visweswaran GR, Leenhouts K, van Roosmalen M, Kok J, Buist G. Exploitingthe peptidoglycan-binding motif, LysM, for medical and industrial applications. Appl Microbiol Biotechnol. 2014;98(10):4331-45. doi: 10.1007/s00253-014-5633-7.
van Roosmalen ML, Kanninga R, El Khattabi M, Neef J, Audouy S, Bosma T, et al. Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteria. Methods. 2006;38(2):144-9. doi: 10.1016/j.ymeth.2005.09.015.
Bosma T, Kanninga R, Neef J, Audouy SA, van Roosmalen ML, Steen A, et al. Novel surface display system for proteins on non-genetically modified gram-positive bacteria. Appl Environ Microbiol. 2006;72(1):880-9. doi: 10.1128/AEM.72.1.880-889.2006.
Van Braeckel-Budimir N, Haijema BJ, Leenhouts K. Bacterium-like particles for efficient immune stimulation of existing vaccines and new subunit vaccines in mucosal applications. Front Immunol. 2013;4:282. doi: 10.3389/fimmu.2013.00282.
Raya-Tonetti F, Muller M, Sacur J, Kitazawa H, Villena J, Vizoso-Pinto MG. Novel LysM motifs for antigen display on lactobacilli for mucosal immunization. Sci Rep. 2021;11(1):21691. doi: 10.1038/s41598-021-01087-8.
Osterman A, Vizoso Pinto MG, Haase R, Nitschko H, Jager S, Sander M, et al. Systematic screening for novel, serologically reactive Hepatitis E Virus epitopes. Virology journal. 2012;9:28. doi: 10.1186/1743-422X 9-28.
Vizoso Pinto MG, Pfrepper KI, Janke T, Noelting C, Sander M, Lueking A, et al. A systematic approach for the identification of novel, serologically reactive recombinant Varicella-Zoster Virus (VZV) antigens. Virology journal. 2010;7:165. doi: 10.1186/1743-422X-7-165.
Domingo C, Gadea I, Pardeiro M, Castilla C, Fernandez S, Fernandez- Clua MA, et al. Immunological properties of a DNA plasmid encoding a chimeric protein of herpes simplex virus type 2 glycoprotein B and glycoproteinD. Vaccine. 2003;21(25-26):3565-74. doi: 10.1016/s0264-410x(03)00423-7.
Arce LP, Raya Tonetti MF, Raimondo MP, Muller MF, Salva S, Alvarez S, et al. Oral Vaccination with Hepatitis E Virus Capsid Protein and Immunobiotic Bacterium-Like Particles Induce Intestinal and Systemic Immunity in Mice. Probiotics and antimicrobial proteins. 2019. doi: 10.1007/s12602-019-09598-7.
LeCureux JS, Dean GA. Lactobacillus Mucosal Vaccine Vectors: Immune Responses against Bacterial and Viral Antigens. mSphere. 2018;3(3).
doi: 10.1128/mSphere.00061-18.
Konstantinov SR, Smidt H, de Vos WM, Bruijns SC, Singh SK, Valence F, et al. S layer protein A of Lactobacillus acidophilus NCFM regulates immature dendritic cell and T cell functions. Proc Natl Acad Sci U S A. 2008;105(49):19474-9. doi: 10.1073/pnas.0810305105.
Song J, Lang F, Zhao N, Guo Y, Zhang H. Vaginal Lactobacilli Induce Differentiation f Monocytic Precursors Toward Langerhans-like Cells: inVitro Evidence. Frontiers in immunology. 2018;9:2437. doi: 10.3389/fimmu.2018.02437. eCollection 2018.
Chentoufi AA, Dhanushkodi NR, Srivastava R, Prakash S, Coulon PA, Zayou L, et al. Combinatorial Herpes Simplex Vaccine Strategies: From Bedside to Bench and Back. Front Immunol. 2022;13:849515. doi: 10.3389/fimmu.2022.849515. eCollection 2022.
Bernstein DI, Flechtner JB, McNeil LK, Heineman T, Oliphant T, Tasker S, et al. Therapeutic HSV-2 vaccine decreases recurrent virus shedding and recurrent genital herpes disease. Vaccine. 2019;37(26):3443-50. doi: 10.1016/j.vaccine.2019.05.009.
Schiffer JT, Swan DA, Corey L, Wald A. Rapid viral expansion and short drug half-life explain the incomplete effectiveness of current herpes simplex virus 2-directed antiviral agents. Antimicrob Agents Chemother. 2013;57(12):5820-9. doi: 10.1128/AAC.01114-13.
Kardani K, Basimi P, Fekri M, Bolhassani A. Antiviral therapy for the sexually transmitted viruses: recent updates on vaccine development. Expert Rev Clin Pharmacol. 2020:1-46. doi: 10.1080/17512433.2020.1814743.
Krishnan R, Stuart PM. Developments in Vaccination for Herpes Simplex Virus. Front Microbiol. 2021;12:798927. doi: 10.3389/fmicb.2021.798927.
ames C, Harfouche M, Welton NJ, Turner KM, Abu-Raddad LJ, Gottlieb SL, et al. Herpes simplex virus: global infection prevalence and incidence estimates, 2016. Bull World Health Organ. 2020;98(5):315-29. doi: 10.2471/BLT.19.237149.
Zhang I, Hsiao Z, Liu F. Development of Genome Editing Approaches against Herpes Simplex Virus Infections. Viruses. 2021;13(2). doi: 10.3390/v13020338.
Du R, Wang L, Xu H, Wang Z, Zhang T, Wang M, et al. A novel glycoprotein D-specific monoclonal antibody neutralizes herpes simplex virus. Antiviral Res. 2017;147:131-41. doi: 10.1016/j.antiviral.2017.10.013.
Burn Aschner C, Pierce C, Knipe DM, Herold BC. Vaccination Route as a Determinant of Protective Antibody Responses against Herpes Simplex Virus. Vaccines (Basel). 2020;8(2). doi: 10.3390/vaccines8020277.
Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, Sacks S, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med. 2002;347(21):1652-61. doi: 10.1056/NEJMoa011915.
Belshe RB, Leone PA, Bernstein DI, Wald A, Levin MJ, Stapleton JT, et al. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med. 2012;366(1):34-43. doi: 10.1056/NEJMoa1103151.
Dropulic LK, Oestreich MC, Pietz HL, Laing KJ, Hunsberger S, LumbardK, et al. A Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of a Replication-Defective Herpes Simplex Virus (HSV) Type 2 Vaccine, HSV529, in Adults With or Without HSV Infection. J Infect Dis. 2019;220(6):990-1000. doi: 10.1093/infdis/jiz225.
Bernard MC, Barban V, Pradezynski F, de Montfort A, Ryall R, Caillet C, et al. Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs. PLoS One. 2015;10(4):e0121518. doi: 10.1371/journal.pone.0121518.
Mestecky J, Moldoveanu Z, Russell MW. Immunologic uniqueness of the genital tract: challenge for vaccine development. Am J Reprod Immunol. 2005;53(5):208-14. doi: 10.1111/j.1600-0897.2005.00267.x.
Michon C, Langella P, Eijsink VG, Mathiesen G, Chatel JM. Display of recombinant proteins at the surface of lactic acid bacteria: strategies and applications. Microbial cell factories. 2016;15:70. doi: 10.1186/s12934-016-0468-9.
Cortes-Perez NG, Bermudez-Humaran LG, Le Loir Y, Rodriguez-Padilla C, Gruss A, Saucedo-Cardenas O, et al. Mice immunization with live lactococci displaying a surface anchored HPV-16 E7 oncoprotein. FEMS Microbiol Lett. 2003;229(1):37-42. doi: 10.1016/S0378-1097(03)00778-X.
Ribelles P, Benbouziane B, Langella P, Suarez JE, Bermudez-Humaran LG. Protection against human papillomavirus type 16-induced tumors in mice using non-genetically modified lactic acid bacteria displaying E7 antigen at its surface. Applied microbiology and biotechnology. 2013;97(3):1231-9. doi: 10.1007/s00253-012-4575-1.
Altindis Edo U, Liberatori S, Soldani E. Inventor Vaccine adjuvants2015.
Cuburu N, Wang K, Goodman KN, Pang YY, Thompson CD, Lowy DR, et al. Topical herpes simplex virus 2 (HSV-2) vaccination with human papilomavirus vectors expressing gB/gD ectodomains induces genitaltissue- resident memory CD8+ T cells and reduces genital disease and viral shedding after HSV-2 challenge. J Virol. 2015;89(1):83-96. doi: 10.1128/JVI.02380-14.
Wizel B, Persson J, Thorn K, Nagy E, Harandi AM. Nasal and skin Delivery of IC31((R))-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes. Vaccine. 2012;30(29):4361-8. doi: 10.1016/j.vaccine.2012.02.019.
Ugozzoli M, O’Hagan DT, Ott GS. Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: the effect of adjuvants on mucosal and serum antibody responses. Immunology. 1998;93(4):563-71. doi: 10.1046/j.1365-2567.1998.00441.x.
Lindqvist M, Persson J, Thorn K, Harandi AM. The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection. Journal of immunology. 2009;182(10):6435-43. doi: 10.4049/jimmunol.0900136.
Lu J, Hou H, Wang D, Leenhouts K, Roosmalen MLV, Sun T, et al. Systemic and mucosal immune responses elicited by intranasal immunization with a pneumococcal bacterium-like particle-based vaccine displaying pneumolysin mutant Plym2. Immunology letters. 2017;187:41-6. doi: 10.1016/j.imlet.2017.05.003.